Form 4 Filing for Cartesian Therapeutics, Inc.

Murat Kalayoglu, a 10% owner of Cartesian Therapeutics, Inc., reported a conversion of Series A Non-Voting Convertible Preferred Stock into Common Stock on April 2, 2026. The trust, benefiting his spouse and children, converted 22,740.03 preferred shares into 758,001 common shares. Following this transaction, the trust holds 33,662.224 preferred shares. Kalayoglu also reported holding 506,999 common shares directly. The conversion is linked to the merger completed on November 13, 2023, where the company acquired Cartesian Therapeutics, Inc. The remaining preferred shares held by the trust are subject to ownership limitations.